Bemcentinib Completed Phase 2 Trials for Acute Myeloid Leukemia / High-risk Myelodysplastic Syndrome (MDS) / Low Risk Myelodysplastic Syndromes Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03824080Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes